APA

Kaumaya P. T. P., Foy K. C., Garrett J., Rawale S. V., Vicari D., Thurmond J. M., Lamb T., Mani A., Kane Y., Balint C. R., Chalupa D., Otterson G. A., Shapiro C. L., Fowler J. M., Grever M. R., Bekaii-Saab T. S. & Carson W. E. (20091117). Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chicago

Kaumaya Pravin T P, Foy Kevin Chu, Garrett Joan, Rawale Sharad V, Vicari Daniele, Thurmond Jennifer M, Lamb Tammy, Mani Aruna, Kane Yahaira, Balint Catherine R, Chalupa Donald, Otterson Gregory A, Shapiro Charles L, Fowler Jeffrey M, Grever Michael R, Bekaii-Saab Tanios S and Carson William E. 20091117. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Harvard

Kaumaya P. T. P., Foy K. C., Garrett J., Rawale S. V., Vicari D., Thurmond J. M., Lamb T., Mani A., Kane Y., Balint C. R., Chalupa D., Otterson G. A., Shapiro C. L., Fowler J. M., Grever M. R., Bekaii-Saab T. S. and Carson W. E. (20091117). Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MLA

Kaumaya Pravin T P, Foy Kevin Chu, Garrett Joan, Rawale Sharad V, Vicari Daniele, Thurmond Jennifer M, Lamb Tammy, Mani Aruna, Kane Yahaira, Balint Catherine R, Chalupa Donald, Otterson Gregory A, Shapiro Charles L, Fowler Jeffrey M, Grever Michael R, Bekaii-Saab Tanios S and Carson William E. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20091117.